Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Elsamitrucin

Next Previous
X
Search
Drug Profile

Elsamitrucin

Alternative Names: BBM 2478A; BMY 28090; Elsamicin A; NSC 369327; SPI-28090

Latest Information Update: 12 Jan 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Bristol-Myers Squibb
  • Developer Assertio Therapeutics
  • Class Aminoglycosides; Benzopyrans; Cytostatic antibiotics
  • Mechanism of Action DNA topoisomerase I inhibitors; Type II DNA topoisomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Solid tumours
  • Discontinued Non-Hodgkin's lymphoma

Most Recent Events

  • 14 Apr 2016 No recent reports on development identified - Phase-I for Solid tumours (Combination therapy, Late-stage disease) in USA (IV)
  • 21 Apr 2011 Elsamitrucin is available for licensing in World (excluding USA) as of 21 Apr 2011. http://www.spectrumpharm.com/
  • 21 Apr 2011 Phase-I clinical trials in late-stage Solid tumours (in combination with paclitaxel) in USA (IV) before April 2011

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top